The Validity, Reliability & Interpretability of Thai-version of Chronic

Status Completed

Clinical Trial Summary

In the majority of patients with the chronic urticaria, the etiology is unclear, leading to difficulties in treatment and high rates of recurrence. According to the International EAACI/GA2LEN/EDF/WAO Guidelines (the Dermatology Section of the European Academy of Allergology and Clinical Immunology(EAACI), the Global Allergy and Asthma European Network (GA2LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) in Urticaria, using the Chronic Urticaria Quality of Life Questionnaire in a routine management is the key for a better treatment outcome. To translate this questionnaire into Thai is essential in our subject of interest in order to effectively apply it to local patients. The Thai-version questionnaire will encourage enhanced as well as impactful therapeutic options for Thai chronic urticaria patients.

Clinical Trial Description

1. Adaption of the Cu-Q2oL questionnaire into Thai version by using forward-backward translation that is independently performed by two bilingual translators. The original Italian version is translated into Thai by two Thai native speakers, then the study team reviews the Thai-version Cu-Q2oL questionnaire for items comprehensibility and integrates the first consensus version which re-translated into Italian by an Italian native speaker afterwards. The comparison between the backward Italian version Cu-Q2oL questionnaire and the original Cu-Q2oL is carried out to find out whether there are any misconception and mistranslation in the intermediary forward version of questionnaire. After that, the second consensus version will be tested on 15 chronic urticaria patients to detect any misunderstanding points based on patients' comments. Finally, this Thai-version of CU-Q2oL questionnaire will be used to investigate the validity, reliability, interpretability and minimal clinical important difference.

2. To investigate the validity, reliability and interpretability of Thai-version of Chronic Urticaria Quality of Life Questionaire (CU-Q2oL), the severity of chronic urticaria symptoms will be assessed by investigators and patients using the Urticaria Activity Score (UAS7), the DLQI and CU-Q2oL questionnaire. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02285023
Study type	Observational
Source	Mahidol University
Contact
Status	Completed
Phase
Start date	November 2014
Completion date	October 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02435238` - AWARE - Chronic Urticaria	N/A
Not yet recruiting	`NCT05513079` - Positive Psychotherapy-Based Counseling (PPT)	N/A
Terminated	`NCT02047136` - Dietary Treatment for Chronic Urticaria	N/A
Completed	`NCT01803763` - Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients	Phase 2/Phase 3
Terminated	`NCT01170949` - Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria	Phase 2
Completed	`NCT00598611` - Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)	Phase 3
Completed	`NCT01610128` - Development of an Urticaria Control Test	N/A
Completed	`NCT02285049` - Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test	N/A
Completed	`NCT01715740` - Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria	Phase 3
Completed	`NCT01960283` - Methotrexate in the Treatment of Chronic Idiopathic Urticaria	Phase 3
Completed	`NCT00481676` - Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria	Phase 2
Completed	`NCT01713725` - Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria	Phase 2
Completed	`NCT01250652` - Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses	Phase 4
Completed	`NCT01111136` - Stress Intervention for Chronic Urticaria	N/A
Recruiting	`NCT01425593` - T Cell Function in Chronic Idiopathic Urticaria	N/A
Completed	`NCT00628108` - Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months	Phase 3
Completed	`NCT00619801` - Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin	Phase 3
Completed	`NCT00737451` - Association of Thyroid Autoimmunity and Chronic Urticaria	N/A
Completed	`NCT01284426` - Natural History of Chronic Urticaria	N/A
Withdrawn	`NCT01073852` - Hydroxychloroquine Efficacy in Chronic Urticaria	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire — CU-Q2oL

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms